
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter D - Drugs for Human Use
#### PART 320 - BIOAVAILABILITY AND BIOEQUIVALENCE REQUIREMENTS
##### Subpart B - Procedures for Determining the Bioavailability or Bioequivalence of Drug Products
###### ยง 320.27 Guidelines on the design of a multiple-dose in vivo bioavailability study.
####### Measurement of an acute pharmacological effect.

(f)When comparison of the test product and the reference material is to be based on acute pharmacological effect-time curves, measurements of this effect should be made with sufficient frequency to demonstrate a maximum effect and a lack of significant difference between the test product and the reference material.
